dc.contributor.advisor | Riederer, Kathleen | |
dc.contributor.author | Chase, Patrick | |
dc.date.accessioned | 2008-03-06T18:56:07Z | |
dc.date.available | 2008-03-06T18:56:07Z | |
dc.date.copyright | 2007-04-27 | |
dc.date.issued | 2007-04-27 | |
dc.identifier.uri | http://hdl.handle.net/10920/4317 | |
dc.description | 1 broadside : ill. | |
dc.description.abstract | Staphylococcus aureus is an aerobic gram positive bacterium that can
cause harmful skin infections and bacteremia. Some strains of S.
aureus have become resistant to synthetic penicillin (Methicillin) and
therefore need to be treated with Daptomycin, a novel lipopeptide
antibiotic that was approved by the Food and Drug Administration
(FDA) for treatment of gram positive skin infections in 2003. Two
patients at St. John Hospital & Medical Center (Detroit, MI) were on
prolonged treatment of Daptomycin for S. aureus bacteremia and blood
cultures showed non-susceptibility to the drug. Both patients’ blood
cultures were shown to develop non-susceptibility to Daptomycin after 5
and 7 days of treatment. | |
dc.description.sponsorship | St. John Hospital and Medical Center (Detroit, Mich.) | |
dc.description.sponsorship | Kalamazoo College. Department of Biology. Diebold Symposium, 2007 | |
dc.description.tableofcontents | Abstract -- Introduction -- Materials and methods -- Results -- Conclusions -- Acknowledgments | |
dc.language.iso | en_US | en |
dc.publisher | Kalamazoo College | |
dc.subject.lcsh | Staphylococcal disease | |
dc.title | Resistance to Daptomycin in the Treatment of Methicillin Resistant Staphylococcus aureus Bacteremia | en |